FOXO1 and neoplasm: They further recorded a better overall survival in PAX7/FOXO1 positive patients (4-year overall survival was 77%) compared to PAX3/FOXO1 positive ones (4-year overall survival was 52%, p = 0.08), based on the primary tumor evaluation [51].